FeesSafety
Pluang+

Ripple's XRP could hit $5, $10, or $28 by 2030 depending on adoption and market growth.

Market News
15 Sep 2026
247 Wallst
View Source
Bullish
Ripple's XRP could hit $5, $10, or $28 by 2030 depending on adoption and market growth.

Ripple's cryptocurrency XRP is trading around $1.40 in 2026, with analysts projecting potential price targets of $5, $10, and $28 by 2030. Each target requires different levels of market growth and adoption: $5 demands a strong market cycle and increased ETF demand; $10 requires evidence of growing activity on the XRP Ledger and institutional adoption; $28 implies XRP surpassing Bitcoin's market cap, needing massive expansion and dominance in crypto. Regulatory clarity, ETF holdings, and increased use in financial infrastructure are key factors influencing these outcomes.

Ripple's XRP price outlook for 2030 is discussed with targets of $5, $10, and $28. For readers following US stocks on Pluang, here is the market snapshot as of Sep 16, 2026 04:03 WIB: out of 150 priced stocks, 57 rose and 92 fell. Notable movers include COIN at USD 171.67 with a 10.33% decline, OPEN at USD 2.64 down 5.38%, and CVNA at USD 67.07 down 5.36%.

More News

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...

Company Fundamentals
Bullish
1 hour ago
Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...

Company Fundamentals
Bullish
1 hour ago
AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...

Others
Neutral
3 hours ago
74.12% of Solana's circulating supply is staked, leaving $15.8B unstaked at current prices

74.12% of Solana's circulating supply is staked, leaving $15.8B unstaked at current prices

As of October 23, 74.12% of Solana's circulating supply, or 437 million SOL, is staked, with 152.6 million SOL unstaked. The unstaked SOL is valued at approximately $15.8 billion based on a price of $103.55 per SOL. The 24-hour trading volume was $2....

Protocol Fundamentals
Neutral
4 hours ago
STRAX token drops 10.48% in one hour but gains 4.49% over 24 hours

STRAX token drops 10.48% in one hour but gains 4.49% over 24 hours

STRAX token experienced a sharp 10.48% decline within a 60-minute period on October 24, falling to $0.01093. Despite this hourly drop, the token maintained a positive 24-hour return of 4.49%, with its price fluctuating between $0.01025 and $0.01221. ...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App